Abcodia appoints President of North America
27 May 2015
UCLB spinout company Abcodia, a specialist company engaged in the development of tests for early detection of cancer, today announced the appointment of Mrs Nadia Altomare as President of North America. Mrs Altomare will develop and implement the strategic business plan for the US operations.
UCLB is a leading technology transfer company that supports and commercialises research and innovations arising from UCL, one of the UK’s top research-led universities.UCLB has a successful track record and a strong reputation for identifying and protecting promising new technologies and innovations from UCL academics. It invests directly in development projects to maximise the potential of the research and manages the commercialisation process of technologies from the laboratory to market.UCLB supports UCL’s Grand Challenges of increasing UCL’s positive impact on and contribution to Global Health, Sustainable Cities, Intercultural Interaction and Human Wellbeing.
For further information, please visit: www.uclb.com
Abcodia is a pioneering UK company engaged in the clinical and commercial development of promising tests for the early detection of cancer. The company’s first product to reach the market in 2015 will be the ROCA® test, to which Abcodia has an exclusive license for the early detection of ovarian cancer. In addition and in co-operation with University College London, Abcodia is leading technology developments in disease lifecycle utilizing the world’s largest serum biobank and clinical database ever developed, to evaluate potential tests for the early detection of disease, including all major cancers. In 2013 Abcodia formed an alliance with Cancer Research UK and Cancer Research Technology to discover and validate blood-based biomarkers that may be used in cancer screening.